Algert Global LLC Increases Stock Holdings in LivaNova PLC $LIVN

Key Points

• Algert Global LLC increased its stake in LivaNova PLC by 49.3% during the first quarter, owning 177,253 shares valued at approximately $6.96 million.
• LivaNova reported a quarterly earnings per share (EPS) of $1.05, surpassing the consensus estimate of $0.84, with revenues increasing 10.6% year-over-year to $352.5 million.
• Analysts have favorable views on LivaNova, with many rating it as a "buy" or "strong-buy" and setting an average target price of $59.29 for the stock.

Algert Global LLC increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 49.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 177,253 shares of the company's stock after acquiring an additional 58,540 shares during the period. Algert Global LLC owned about 0.33% of LivaNova worth $6,962,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UMB Bank n.a. lifted its stake in shares of LivaNova by 340.5% during the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after acquiring an additional 647 shares during the last quarter. CWM LLC raised its position in LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after purchasing an additional 299 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in LivaNova by 415.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock valued at $58,000 after purchasing an additional 1,184 shares in the last quarter. Russell Investments Group Ltd. raised its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Finally, Sterling Capital Management LLC raised its position in LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Up 5.8%

LIVN stock traded up $3.04 on Friday, hitting $55.90. 728,016 shares of the company's stock were exchanged, compared to its average volume of 806,134. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $57.35. The firm has a 50 day moving average price of $46.42 and a two-hundred day moving average price of $43.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The stock has a market cap of $3.05 billion, a P/E ratio of -14.37 and a beta of 0.92.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. During the same period in the previous year, the business earned $0.93 EPS. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. As a group, equities research analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

LIVN has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. Robert W. Baird lifted their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Barclays lifted their target price on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday. Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research report on Tuesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.